Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LH
stocks logo

LH

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
3.56B
+6.93%
3.938
+14.14%
3.50B
+4.63%
4.111
+7.05%
3.68B
+4.27%
4.638
+6.62%
Estimates Revision
The market is revising Downward the revenue expectations for Labcorp Holdings Inc. (LH) for FY2025, with the revenue forecasts being adjusted by -0.07% over the past three months. During the same period, the stock price has changed by -5.00%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.07%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.08%
In Past 3 Month
Stock Price
Go Down
down Image
-5.00%
In Past 3 Month
Wall Street analysts forecast LH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LH is 307.00 USD with a low forecast of 270.00 USD and a high forecast of 342.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast LH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LH is 307.00 USD with a low forecast of 270.00 USD and a high forecast of 342.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 261.480
sliders
Low
270.00
Averages
307.00
High
342.00
Current: 261.480
sliders
Low
270.00
Averages
307.00
High
342.00
Piper Sandler
David Westenberg
Neutral
downgrade
$280 -> $270
2025-11-10
Reason
Piper Sandler
David Westenberg
Price Target
$280 -> $270
2025-11-10
downgrade
Neutral
Reason
Piper Sandler analyst David Westenberg lowered the firm's price target on Labcorp to $270 from $280 following quarterly results. The firm keeps a Neutral rating on the shares.
JPMorgan
NULL -> Overweight
maintain
$291 -> $317
2025-11-07
Reason
JPMorgan
Price Target
$291 -> $317
2025-11-07
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Labcorp to $317 from $291 and keeps an Overweight rating on the shares. The firm updated the company's model.
UBS
Kevin Caliendo
Buy
downgrade
$325 -> $320
2025-10-29
Reason
UBS
Kevin Caliendo
Price Target
$325 -> $320
2025-10-29
downgrade
Buy
Reason
UBS analyst Kevin Caliendo lowered the firm's price target on Labcorp to $320 from $325 and keeps a Buy rating on the shares.
Baird
Outperform -> Outperform
downgrade
$313 -> $304
2025-10-29
Reason
Baird
Price Target
$313 -> $304
2025-10-29
downgrade
Outperform -> Outperform
Reason
Baird lowered the firm's price target on Labcorp to $304 from $313 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results.
Mizuho
Ann Hynes
Outperform
maintain
$285 -> $320
2025-10-17
Reason
Mizuho
Ann Hynes
Price Target
$285 -> $320
2025-10-17
maintain
Outperform
Reason
Mizuho analyst Ann Hynes raised the firm's price target on Labcorp to $320 from $285 and keeps an Outperform rating on the shares as part of a Q3 earnings preview for the healthcare facilities and managed care group. Healthcare utilization growth trends decelerated sequentially in Q3 despite easier year-over-year compares, which could indicate stabilizing cost trends, a positive for managed care companies, the analyst tells investors in a research note. The firm expects solid results from hospitals despite admissions trends falling sequentially. It is also "cautiously optimistic" that contract research organization trends have bottomed.
UBS
Buy
maintain
$305 -> $325
2025-10-17
Reason
UBS
Price Target
$305 -> $325
2025-10-17
maintain
Buy
Reason
UBS raised the firm's price target on Labcorp to $325 from $305 and keeps a Buy rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Labcorp Holdings Inc (LH.N) is 15.46, compared to its 5-year average forward P/E of 14.51. For a more detailed relative valuation and DCF analysis to assess Labcorp Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
14.51
Current PE
15.46
Overvalued PE
16.51
Undervalued PE
12.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
10.63
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
11.88
Undervalued EV/EBITDA
9.38

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.55
Current PS
0.00
Overvalued PS
1.75
Undervalued PS
1.35
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 676.52% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

LH News & Events

Events Timeline

(ET)
2025-11-24
08:33:00
Labcorp Names Victor Bulto to Its Board of Directors
select
2025-11-13 (ET)
2025-11-13
11:49:54
Hims & Hers views lab testing as a billion-dollar opportunity, according to WSJ.
select
link
2025-10-28 (ET)
2025-10-28
06:57:05
Labcorp updates FY25 adjusted EPS forecast to a range of $16.15-$16.50, down from $16.05-$16.50
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
12-03Newsfilter
Community Health Systems Sells Laboratory Assets to Labcorp for $194 Million
  • Transaction Completion: Community Health Systems' subsidiary CHS has successfully sold select ambulatory outreach laboratory service assets in 13 states to Labcorp for approximately $194 million in cash, enhancing patient and provider access to high-quality laboratory services.
  • Service Focus: This transaction allows Community Health Systems to concentrate on core services, improving the overall patient experience and reinforcing its commitment to providing high-quality healthcare.
  • Technological Support: Labcorp's scale and investment in technology will enable efficient delivery of outreach laboratory services, thereby improving patient care and driving efficiencies for customers, aligning with both companies' shared commitment to enhancing community health.
  • Strategic Relationships: This transaction is part of Labcorp's strategy to establish relationships with various health systems, aimed at increasing access to laboratory services, improving patient care, and driving efficiencies for customers.
[object Object]
Preview
8.0
11-24NASDAQ.COM
Upcoming Ex-Dividend Dates for PVH, Brunswick, and Labcorp Holdings

  • Upcoming Ex-Dividend Dates: On 11/26/25, PVH Corp, Brunswick Corp, and Labcorp Holdings Inc will trade ex-dividend, with respective dividends of $0.0375, $0.43, and $0.72 scheduled for payment on 12/17/25, 12/15/25, and 12/11/25.

  • Expected Price Adjustments: Following the ex-dividend dates, shares of PVH Corp, Brunswick Corp, and Labcorp Holdings Inc are expected to open lower by approximately 0.05%, 0.67%, and 0.27%, respectively.

  • Dividend Yield Estimates: The estimated annualized dividend yields are 0.20% for PVH Corp, 2.68% for Brunswick Corp, and 1.08% for Labcorp Holdings Inc, reflecting the companies' historical dividend stability.

  • Current Stock Performance: As of Monday trading, PVH Corp shares are up 5.3%, Brunswick Corp shares are up 8.2%, and Labcorp Holdings Inc shares are up 1.6%.

[object Object]
Preview
5.0
11-24Newsfilter
Labcorp Appoints Novartis Executive Victor Bulto to Board, Enhancing Long-Term Growth Strategy
  • Executive Appointment: Labcorp has appointed Victor Bulto to its Board of Directors, effective December 1, 2025. With 25 years of experience in the pharmaceutical industry and overseeing Novartis' $20 billion U.S. business, Bulto is expected to bring valuable insights and leadership to Labcorp.
  • Strategic Impact: Bulto's addition will enhance Labcorp's focus on innovation and global healthcare leadership. His expertise in oncology, immunology, neuroscience, and cardiovascular-renal-metabolic areas will help the company seize opportunities in the rapidly evolving field of precision medicine.
  • Market Outlook: Labcorp's CEO Adam Schechter noted that Bulto's experience will drive the company's strategic priorities in scientific and technological innovation, enhancing value for customers and shareholders. This appointment reflects the company's confidence in future healthcare developments, particularly in accelerating access to new therapies and patient impact.
  • Company Background: Labcorp is a global leader in laboratory services, employing nearly 70,000 people and serving clients in approximately 100 countries. The company supported over 75% of new drugs and therapeutic products approved by the FDA in 2024, performing more than 700 million tests annually, highlighting its significant role in the industry.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Labcorp Holdings Inc (LH) stock price today?

The current price of LH is 261.48 USD — it has decreased -1.61 % in the last trading day.

arrow icon

What is Labcorp Holdings Inc (LH)'s business?

Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and accelerates to improve health and improve lives through its unparalleled diagnostics and drug development capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.

arrow icon

What is the price predicton of LH Stock?

Wall Street analysts forecast LH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LH is 307.00 USD with a low forecast of 270.00 USD and a high forecast of 342.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Labcorp Holdings Inc (LH)'s revenue for the last quarter?

Labcorp Holdings Inc revenue for the last quarter amounts to 3.56B USD, increased 8.58 % YoY.

arrow icon

What is Labcorp Holdings Inc (LH)'s earnings per share (EPS) for the last quarter?

Labcorp Holdings Inc. EPS for the last quarter amounts to 3.12 USD, increased 55.22 % YoY.

arrow icon

What changes have occurred in the market's expectations for Labcorp Holdings Inc (LH)'s fundamentals?

The market is revising Downward the revenue expectations for Labcorp Holdings Inc. (LH) for FY2025, with the revenue forecasts being adjusted by -0.07% over the past three months. During the same period, the stock price has changed by -5.00%.
arrow icon

How many employees does Labcorp Holdings Inc (LH). have?

Labcorp Holdings Inc (LH) has 70000 emplpoyees as of December 05 2025.

arrow icon

What is Labcorp Holdings Inc (LH) market cap?

Today LH has the market capitalization of 21.68B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free